InsidersTradesSigma
Follow the Belite Bio, Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Market capitalisation: €6.1bn. The latest transaction was reported on 12 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Dr. Hendrick P. Scholl. Every trade is free.
Analysts rate Belite Bio, Inc. Strong Buy (bullish), based on 8 analysts. Average price target: US$214.00.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
4 of 4 declarations
Belite Bio, Inc. es una empresa biofarmacéutica centrada en el desarrollo de tratamientos para enfermedades de la retina. Cotiza en el NASDAQ bajo el símbolo BLTE.